Scott Kitchener
Griffith University
58 Papers
313 Citations
Scott Kitchener is an academic researcher from Griffith University. The author has contributed to research in topics: Medicine & Primaquine. The author has an hindex of 16, co-authored 54 publications. Previous affiliations of Scott Kitchener include James Cook University & University of Queensland.
Chat about Author
Papers
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Farshad Guirakhoo,Scott Kitchener,Dennis Morrison,Remi Forrat,Karen McCarthy,Richard A. Nichols,Sutee Yoksan,Xiaochu Duan,Thomas H. Ermak,Niranjan Kanesa-thasan,Philip Bedford,Jean Lang,Marie-Jose Quentin-Millet,Thomas P. Monath +13 more
TL;DR: Surprisingly, levels of neutralizing antibodies to DEN 1, 2, and 3 viruses in YF immune subjects persisted after 1 year, and can have practical implications toward development of a dengue vaccine.
213
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Scott Kitchener,Michael D. Nissen,Peter Nasveld,Remi Forrat,Sutee Yoksan,Jean Lang,Jean-François Saluzzo +6 more
TL;DR: In this paper, the authors conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers.
135
Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects
Peter Nasveld,Michael D. Edstein,Mark Reid,Leonard Brennan,Ivor Harris,Scott Kitchener,Peter A. Leggat,Philip Pickford,Caron Kerr,Colin Ohrt,William R Prescott +10 more
TL;DR: Although the volunteers' precise exposure to malaria could not be proven in this study, tafenoquine appears to be a highly efficacious drug for malaria prophylaxis.
117
The Efficacy and Tolerability of Three Different Regimens of Tafenoquine Versus Primaquine for Post-Exposure Prophylaxis of Plasmodium Vivax Malaria in the Southwest Pacific
TL;DR: There was a dose-dependent reduction in adverse events with a reduced dose of tafenoquine, with the lowest dose producing rates of adverse events equivalent to that of primaquine plus doxycycline.
60
Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel
TL;DR: On return from duty in North Solomons Province, Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14-d) or tafenoquine (3-D) post-exposure malaria prophylaxis and overall, volunteers preferred the shorter course of tafanoquine.
49